Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 72162-1058

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 72162-1058). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Duloxetine 60 mg delayed-release pellets capsule, oral dosage form, labeled by Bryant Ranch Prepack. The capsule features a blue and gray body with printed text on the blue portion. The image shows a single capsule oriented horizontally.*

FDA Label Image

Figure6 (Image 10)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine at doses of 120 mg once daily, 60 mg once daily, 20 mg once daily, and a placebo. Each treatment is represented by a different line style and marker, with data points decreasing as percent improvement increases.*

FDA Label Image

Figure 7 (Image 11)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine delayed-release 60 mg once daily and placebo, with the Duloxetine group consistently showing higher percentages of patients improved across various pain improvement thresholds.*

FDA Label Image

Figure8 (Image 12)

Line graph comparing the percentage of patients improved over percent improvement in pain from baseline (BOCF) between placebo and Duloxetine delayed-release 60 mg/120 mg once daily. The graph displays two curves showing patient improvement trends across increasing pain improvement percentages.*

FDA Label Image

Figure9 (Image 13)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and Duloxetine delayed-release 60 mg once daily. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved. Two lines represent placebo and Duloxetine treatment groups, illustrating higher improvement rates with Duloxetine across most pain improvement thresholds.*

FDA Label Image

Figure10 (Image 14)

A line graph comparing percentage improvement in pain from baseline (BOCF) on the x-axis with the percentage of patients improved on the y-axis. It shows two data series: placebo (dashed line with x markers) and Duloxetine delayed-release 60/120 mg once daily (solid line with diamond markers). The graph illustrates patient response rates at various improvement thresholds.*

FDA Label Image

1 (Image 2)

Duloxetine 60 mg delayed release pellets capsule, oral dosage form. The capsule contains pellet beads visible inside a clear gelatin shell with orange and light beige colored sections. Labeled by Bryant Ranch Prepack, the image shows a single capsule.*

FDA Label Image

1 (Image 3)

Chemical structure of duloxetine, illustrating its molecular composition with a naphthalene moiety and a thiophene group, associated with the antidepressant duloxetine active ingredient.*

FDA Label Image

1 (Image 4)

Chemical structure diagram of Duloxetine, illustrating its molecular framework including aromatic rings, sulfur-containing thiophene ring, and amine group with associated hydrochloride.*

FDA Label Image

Figure1 (Image 5)

Kaplan-Meier survival curve showing the proportion of patients with relapse over time (days) from randomization, comparing Duloxetine delayed-release capsules with placebo. The graph illustrates relapse rates until approximately 200 days, with Duloxetine showing a lower proportion of patients with relapse compared to placebo.*

FDA Label Image

Figure2 (Image 6)

A Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time from randomization in days. It compares Duloxetine delayed-release capsules (solid line) to placebo (dashed line), illustrating lower relapse rates in patients treated with Duloxetine over a period up to 250 days.*

FDA Label Image

Figure3 (Image 7)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg taken twice daily (BID), 60 mg once daily (QD), 20 mg QD, and placebo, illustrating pain improvement trends across different Duloxetine dosages compared to placebo.*

FDA Label Image

Figure4 (Image 8)

The image is a line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares patients treated with Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, showing the trend of patient improvement across increasing pain relief percentages.*

FDA Label Image

Figure5 (Image 9)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis represents percent improvement in pain, while the y-axis shows the percentage of patients improved. The graph includes three distinct lines for each treatment group.*

FDA Label Image

Label (Lbl721621058)

The label for Duloxetine Delayed-Release Capsules, USP 60 mg, shows the NDC 72162-1058-3. It includes a quantity of 30 capsules and is marked Rx only. The label indicates it is relabeled by Bryant Ranch Prepack, Inc. and manufactured by Actavis Pharma, Inc. Storage instructions and safety warnings are also displayed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.